Dr. Shapiro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
# M446
Boston, MA 02215Phone+1 617-632-4942Fax+1 617-632-1977- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1994
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1988 - 1991
- Weill Cornell MedicineClass of 1988
- Weill-Cornell Graduate School of Medical SciencesPh.D., 1987
- Columbia College, Columbia UniversityB.A., Biochemistry, Magna Cum Laude, 1981
Certifications & Licensure
- MA State Medical License 1991 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Castle Connolly's Regional Top Doctors Castle Connolly, Ltd., 2014
- Michaele C. Christian Oncology Development Award CTEP, NCI, 2013
- Join now to see all
Clinical Trials
- Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 Jan 01
- Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies Start of enrollment: 2003 Aug 01
- Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.Funda Meric-Bernstam, Michael W Lloyd, Soner Koc, Yvonne A Evrard, Lisa Meier McShane, Michael T Lewis, Kurt W Evans, Dali Li, Lawrence V Rubinstein, Alana L Welm, Den...> ;Molecular Cancer Therapeutics. 2024 Apr 20
- Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, Alexandre André B A da Costa, Doga Gulhan, Andrea E Wahner Hendrickson, Bose Kochupurakkal, David L Kol...> ;JCO Precision Oncology. 2024 Apr 1
- Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
- Join now to see all
Journal Articles
- KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
- Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer PopulationKhanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
- Phase I safety, pharmacokinetic and pharmacodynamics study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in pa...LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Ca..., Clin Cancer Res, 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.George S, Barysauskas CM, Solomon S, Tahlil K, Malley R, Hohos M, Polson K, Loucks M, Wagner AJ, Merriam P, Morgan JA, Rodig SJ, Hodi SF, Shapiro G, Demetri GD, J Clin Oncol, 1/1/2016
- In vivo synergism between PARP inhibitor olaparib and HSP90 ihibitor AT13387 in high-grade serous ovarian cancer patient-derived xenografts.Konstantinopoulos P, Palakurthi S, Zeng Q, Zhou S, Liu JF, Ivanova E, Paweletz C, Kommajosyula N, D’Andrea AD, Shapiro G, Matulonis UA, J Clin Oncol, 1/1/2016
- A Phase 1 study of MLN0128 and bevacizumab in patients with recurrent glioblastoma or other solid tumors.Nayak L, Hays JL, Muzikansky A, Gaffey SC, Do KT, Puduvalli VK, Lee EQ, Rinne ML, Norden AD, Beroukhim R, Wen PY, Doyle LA, Chen HX, Shapiro G, Reardon D, J Clin Oncol, 1/1/2016
- Join now to see all
Lectures
- Developmental Therapeutics and Tumor Biology (Nonimmuno)ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Join now to see all
Other
- Small molecule inhibitors of cyclin-dependent kinases. In: M.V. Blagosklonny, editor. Cell Cycle Checkpoints and Cancer.Shapiro GI, Landes Bioscience
Georgetown, TX - 1/1/2001 - Thesis: Influenza virus gene expression: viral RNA replication in vivo and in vitro.Shapiro GI, Weill-Cornell Graduate School of Medical Sciences,
Cornell University - 1/1/1987
Press Mentions
- Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study ShowsMarch 14th, 2023
- Computer Platform Helps Match Patients with Cancer to Trials of Targeted TherapyOctober 12th, 2022
- Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
- Join now to see all
Grant Support
- Cyclin-Dependent Kinase Inhibition During S PhaseNational Cancer Institute2010–2012
- Translational Studies Of HSP90 Inhibitors In NsclcNational Cancer Institute2008–2009
- Flavopiridol Mediated Apoptosis During S PhaseNational Cancer Institute2004–2008
- Flavopiridol Mediated Apoptosis During S Phase In NsclcNational Cancer Institute2001–2003
- Identification Of Cyclin C Associated ProteinsNational Cancer Institute1997–1998
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: